Emicizumab

Publication Details

Estimated reading time: 1 minute

CASRN: 1610943-06-0

Drug Levels and Effects

Summary of Use during Lactation

A low level of emicizumab was found in the milk of one woman. The drug is likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[2]

Drug Levels

Maternal Levels. A woman with severe hemophilia A received emicizumab every 4 weeks (dose not stated, but probably 6 mg/kg) throughout pregnancy and postpartum as well as recombinant factor VIIa (NovoSeven) 90 mcg/kg every 2 hours initially with a gradually increasing dosage interval postpartum for severe bleeding. A milk sample taken at an unreported time contained 38 mg/L of emicizumab.[3]

Infant Levels. A woman with severe hemophilia A was receiving emicizumab every 4 weeks (dose not stated, but probably 6 mg/kg) throughout pregnancy and postpartum as well as recombinant factor VIIa (NovoSeven) 90 mcg/kg every 2 hours initially with a gradually increasing dosage interval postpartum for severe bleeding. A serum sample taken from the infant at an unreported time contained 106 mg/L of emicizumab, probably obtained transplacentally.[3]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
2.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]
3.
Kharel Z, Pruthi RK, Kouides PA, Reid R. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Blood 2023;142:5492. doi:10.1182/blood-2023-190012 [PubMed: 38650315] [CrossRef]

Substance Identification

Substance Name

Emicizumab

CAS Registry Number

1610943-06-0

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Bispecific

Antibodies, Monoclonal, Humanized

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.